Patent details
EP2900240 Title: CRYSTALLINE FORM OF A REVERSE TRANSCRIPTASE INHIBITOR
Basic Information
- Publication number:
- EP2900240
- PCT Application Number:
- US2013060787
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP138403795
- PCT Publication Number:
- WO2014052171
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- CRYSTALLINE FORM OF A REVERSE TRANSCRIPTASE INHIBITOR
- French Title of Invention:
- FORME CRISTALLINE D'INHIBITEUR DE TRANSCRIPTASE INVERSE
- German Title of Invention:
- KRISTALLINE FORM EINES REVERSE-TRANSKRIPTASE-INHIBITORS
- SPC Number:
Dates
- Filing date:
- 20/09/2013
- Grant date:
- 08/01/2020
- EP Publication Date:
- 05/08/2015
- PCT Publication Date:
- 03/04/2014
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 08/01/2020
- EP B1 Publication Date:
- 08/01/2020
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 20/09/2020
- Expiration date:
- 20/09/2033
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 01/01/2020
- Name:
- Merck Sharp & Dohme Corp.
- Address:
- 126 East Lincoln Avenue, Rahway, NJ 07065-0907, United States (US)
Inventor
- Name:
- MAGUIRE, Courtney, K.
- Address:
- United States (US)
Priority
- Priority Number:
- 201261705780 P
- Priority Date:
- 26/09/2012
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 31/4439; C07D 401/06;
Publication
European Patent Bulletin
- Issue number:
- 202002
- Publication date:
- 08/01/2020
- Description:
- Grant (B1)
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|